Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
AURA 
Aura Biosciences Inc (AURA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: AURA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $21.2
1 Year Target Price $21.2
| 4 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -53.56% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 336.07M USD | Price to earnings Ratio - | 1Y Target Price 21.2 |
Price to earnings Ratio - | 1Y Target Price 21.2 | ||
Volume (30-day avg) 7 | Beta 0.45 | 52 Weeks Range 4.34 - 11.22 | Updated Date 11/7/2025 |
52 Weeks Range 4.34 - 11.22 | Updated Date 11/7/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.95 |
Earnings Date
Report Date 2025-11-06 | When - | Estimate -0.462 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -32.14% | Return on Equity (TTM) -55.39% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 214762635 | Price to Sales(TTM) - |
Enterprise Value 214762635 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -5.68 | Shares Outstanding 62119873 | Shares Floating 35280361 |
Shares Outstanding 62119873 | Shares Floating 35280361 | ||
Percent Insiders 1.93 | Percent Institutions 84.67 |
Upturn AI SWOT
Aura Biosciences Inc
Company Overview
History and Background
Aura Biosciences Inc. is a biotechnology company focused on developing therapies to treat cancer. Founded in 2009, Aura is pioneering a new class of therapies based on viral capsid conjugates.
Core Business Areas
- Aura's Core Product Candidate: Aura is developing AU-011 (belzupacap sarotalocan), a novel targeted therapy for the treatment of primary choroidal melanoma, a rare and life-threatening form of eye cancer.
Leadership and Structure
Dr. Elisabet de los Pinos is the CEO of Aura Biosciences. The company has a board of directors and a management team overseeing research and development, clinical operations, and corporate strategy.
Top Products and Market Share
Key Offerings
- AU-011 (belzupacap sarotalocan): AU-011 is Aura's lead product candidate, being developed for the treatment of choroidal melanoma. The treatment is designed to selectively target and destroy cancer cells in the eye. As a development-stage product, it currently generates no revenue. Competitors are conventional treatments for choroidal melanoma such as radiation therapy or enucleation.
Market Dynamics
Industry Overview
The biotechnology industry is focused on developing novel therapeutics for various diseases. The oncology segment is a significant driver of growth in the biotech industry, with a large unmet need for effective cancer treatments.
Positioning
Aura Biosciences is positioned as an innovative company developing targeted therapies for rare cancers. Its competitive advantage lies in its viral capsid conjugate technology, which offers a unique approach to selectively target cancer cells.
Total Addressable Market (TAM)
The estimated TAM for choroidal melanoma treatment is substantial, given the limited treatment options currently available and the potential for AU-011 to become a standard of care. Accurate TAM figures are difficult to determine before commercialization, but the company addresses a critical unmet need.
Upturn SWOT Analysis
Strengths
- Novel targeted therapy platform
- Lead product candidate in clinical development
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- Reliance on a single product candidate
- Clinical trial risks
- Need for regulatory approval
- Potential for competition from other therapies
Opportunities
- Expansion into other cancer indications
- Partnerships with pharmaceutical companies
- Positive clinical trial results
- Orphan drug designation benefits
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established therapies
- Funding constraints
Competitors and Market Share
Key Competitors
- ALEC
- FHTX
Competitive Landscape
Aura competes with companies developing other treatments for choroidal melanoma, including radiation therapies and surgical procedures. Its advantage lies in the targeted nature of AU-011.
Growth Trajectory and Initiatives
Historical Growth: Aura's growth has been focused on advancing AU-011 through clinical development.
Future Projections: Future growth is contingent on successful clinical trials, regulatory approvals, and commercialization of AU-011.
Recent Initiatives: Recent initiatives include ongoing clinical trials, presentations at scientific conferences, and investor relations activities.
Summary
Aura Biosciences is a clinical-stage biotechnology company focused on developing therapies for rare cancers, primarily choroidal melanoma. The company's success hinges on the clinical development and regulatory approval of AU-011. While Aura's targeted therapy approach is promising, clinical trial risks and regulatory hurdles present significant challenges. Continued financial backing and positive clinical data will be essential for Aura's future growth.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Aura Biosciences Inc. company website
- SEC Filings
- Industry Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aura Biosciences Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2021-10-29 | Founder, CEO, President & Director Dr. Elisabet de los Pinos Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 106 | Website https://www.aurabiosciences.com |
Full time employees 106 | Website https://www.aurabiosciences.com | ||
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer, as an alternative to bacillus calmette"guérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.